avutometinib,defactinib
verastem oncology
['ovarian', 'gyn', 'avutometinib']
 the combination of avutometinib (raf/mek clamp) and defactenib (fak inhibitor) demonstrates impressive activity in low grade serous #ovariancancer, with higher efficacy in tumors that have ras aberrations
#asco23 #gyncsm 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. @ASCO_JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc